Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Opioid Treatments Could Get Survival Claim As US FDA Develops Protocol

Executive Summary

Commissioner Gottlieb announces several actions in the works to promote development of new treatments for opioid addiction, including guidance on how to establish novel endpoints.

You may also be interested in...



Opioid Use Disorder: Is Reduced Usage A Better Endpoint Than Abstinence?

Some at patient-focused drug development meeting argue that cutting opioid use should not be considered treatment failure and that medications allowing controlled opioid use may be beneficial.

FDA's Kratom Campaign Turns To Firms Destroying Inventory, Recalling Products

FDA announcement that Missouri firm Divinity Products will recall and destroy kratom was part of the agency's latest warning that ingredients derived from the herb are not safe for use in supplements or for therapeutic use to treat symptoms of withdrawal from opioid abuse. FDA doesn't get agreement from the kratom sector about the herb's status as a dietary ingredient as well as its safety profile.

BIO Report: Attrition Higher For Novel Pain Candidates Than In Other Diseases, Funding Lacking

A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS122068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel